Transforming Infrastructure for Optimal CGT Development Processes
Cell and gene therapies (CGTs) are paving the way for advanced disease treatments and personalized medicines, with several already gaining FDA approval. However, one major challenge faced by CGT companies is the inefficiencies in their infrastructure, hindering the development of life-saving therapeutics. ElevateBio recognized these bottlenecks and set out to revolutionize CGT development by leveraging a groundbreaking solution. Through Benchling's integrated technologies model, ElevateBio is empowering the acceleration of design, manufacturing, and development of various genetic medicines. This unique platform offers turnkey scale and biotechnological capabilities, enabling CGT processes and programs to reach their full potential.
Empowering CGT Innovators with Next-Generation Technology Platforms
ElevateBio is playing a pivotal role in supporting a diverse range of CGT innovators, from startups to large biopharmaceutical companies. By providing access to cutting-edge technology platforms, manufacturing capabilities, and top-tier expertise, ElevateBio is fostering a new era of advancements in cell and gene therapy research. The company's R&D organization, backed by a skilled next-generation sequencing (NGS) team, is dedicated to developing innovative therapeutics and technologies that can drive breakthroughs in the field. Collaborating with Benchling, ElevateBio has created a robust infrastructure to fuel the development of key capabilities and expertise, leading to enhanced productivity and success rates.
Realizing Significant Enhancements in Performance and Efficiency
The adoption of Benchling has yielded remarkable results for ElevateBio, showcasing significant improvements in multiple areas. The NGS core team saw a substantial increase in sample throughput, processing hundreds to thousands of samples weekly. This surge in efficiency not only boosted scientist productivity but also expedited the identification of process bottlenecks, allowing for faster achievement of breakthroughs. With Benchling's centralized platform, ElevateBio successfully established a high-throughput CGT research pipeline, addressing the challenges of managing vast amounts of data and accelerating research timelines.
Maximizing Success through Streamlined Data Management and Enhanced Traceability
ElevateBio's commitment to excellence is evident in its mission to maximize success rates through enhanced data management and traceability. By utilizing Benchling, the company eliminated manual data management tasks, enabling scientists to focus on core research activities. The standardized data capture processes and digital trail capabilities facilitated by Benchling have enhanced collaboration and decision-making across teams, leading to improved outcomes. Moreover, the platform's ability to identify inefficiencies earlier in the R&D process and provide full traceability of samples has significantly increased ElevateBio's success rates, making it a trailblazer in the cell and gene therapy landscape.